CN103328005A - 基于将到抗体的佐剂直接靶向抗原呈递细胞的新型疫苗佐剂 - Google Patents
基于将到抗体的佐剂直接靶向抗原呈递细胞的新型疫苗佐剂 Download PDFInfo
- Publication number
- CN103328005A CN103328005A CN2011800489046A CN201180048904A CN103328005A CN 103328005 A CN103328005 A CN 103328005A CN 2011800489046 A CN2011800489046 A CN 2011800489046A CN 201180048904 A CN201180048904 A CN 201180048904A CN 103328005 A CN103328005 A CN 103328005A
- Authority
- CN
- China
- Prior art keywords
- antigen
- antigens
- cancer
- composition
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/106—Vibrio; Campylobacter; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37376310P | 2010-08-13 | 2010-08-13 | |
| US61/373763 | 2010-08-13 | ||
| PCT/US2011/047633 WO2012021834A1 (en) | 2010-08-13 | 2011-08-12 | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103328005A true CN103328005A (zh) | 2013-09-25 |
Family
ID=45564978
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011800489046A Pending CN103328005A (zh) | 2010-08-13 | 2011-08-12 | 基于将到抗体的佐剂直接靶向抗原呈递细胞的新型疫苗佐剂 |
Country Status (14)
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104689313A (zh) * | 2015-03-04 | 2015-06-10 | 中国科学院海洋研究所 | 大菱鲆cd83分子作为疫苗佐剂的应用 |
| CN106170299A (zh) * | 2014-01-22 | 2016-11-30 | 小利兰斯坦福大学托管委员会 | 用于抗体和抗体负载树突状细胞介导治疗的方法和组合物 |
| CN106456736A (zh) * | 2014-06-02 | 2017-02-22 | 贝勒研究院 | 用于治疗过敏和炎性疾病的方法和组合物 |
| CN107098970A (zh) * | 2007-05-03 | 2017-08-29 | 新加坡科技研究局 | 结合细胞内prl‑1多肽或prl‑3多肽的抗体 |
| CN108430498A (zh) * | 2015-11-10 | 2018-08-21 | 耶鲁大学 | 用于治疗自身免疫疾病和癌症的组合物及方法 |
| CN108727503A (zh) * | 2017-04-18 | 2018-11-02 | 武汉博沃生物科技有限公司 | VZV重组gE-鞭毛素融合蛋白及其制备方法和应用 |
| CN111432833A (zh) * | 2017-11-29 | 2020-07-17 | 自适应噬菌体治疗公司 | 使用二十面体噬菌体的疫苗接种方法 |
| CN111801100A (zh) * | 2018-02-28 | 2020-10-20 | 豪夫迈·罗氏有限公司 | 用于治疗和预防肝癌的7-取代的磺亚氨酰基嘌呤酮化合物和衍生物 |
| US11110178B2 (en) | 2016-07-07 | 2021-09-07 | The Board Of Trustees Of The Leland Standford Junior University | Antibody adjuvant conjugates |
| CN113811547A (zh) * | 2019-03-27 | 2021-12-17 | 国家医疗保健研究所 | 具有cd40激活特性的重组蛋白 |
| US11400164B2 (en) | 2019-03-15 | 2022-08-02 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體(dc-asgpr)接合抗原呈現細胞之藥劑 |
| WO2012122396A1 (en) * | 2011-03-08 | 2012-09-13 | Baylor Research Institute | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells |
| AR088220A1 (es) * | 2011-08-29 | 2014-05-21 | Baylor Res Inst | Activacion de celulas dendriticas humanas por el receptor de dectina-1 o de tipo toll 2 (tlr2) en el control de la alergia y el asma |
| WO2013134293A1 (en) * | 2012-03-05 | 2013-09-12 | Duke University | Vaccine formulation |
| CN112587671A (zh) * | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| WO2014031984A1 (en) * | 2012-08-24 | 2014-02-27 | Baylor Research Institute | Immunological detection methods and compositions |
| WO2014210540A1 (en) | 2013-06-28 | 2014-12-31 | Baylor Research Institute | Dendritic cell asgpr targeting immunotherapeutics for multiple sclerosis |
| CN103409451A (zh) * | 2013-06-28 | 2013-11-27 | 扬州维克斯生物科技有限公司 | 一种向树突状细胞dc靶向加载肿瘤抗原肽的方法 |
| AU2014315081A1 (en) | 2013-09-05 | 2016-03-24 | Duke University | Nav1.7 antibodies and methods of using the same |
| EP3092256B1 (en) | 2014-01-10 | 2022-05-18 | Birdie Biopharmaceuticals Inc. | Compounds and compositions for immunotherapy |
| WO2015106281A1 (en) | 2014-01-13 | 2015-07-16 | Baylor Research Institute | Novel vaccines against hpv and hpv-related diseases |
| IL300029A (en) | 2014-05-16 | 2023-03-01 | Baylor Res Institute | Methods and preparations for the treatment of autoimmune and inflammatory conditions |
| MX2016017393A (es) | 2014-07-01 | 2017-09-05 | Pfizer | Diacuerpos heterodimericos biespecificos y sus usos. |
| DK4001311T3 (da) | 2014-07-09 | 2026-02-02 | Birdie Biopharmaceuticals Inc | Anti-pd-l1/pd-1-kombinationer til behandling af tumorer |
| CN112546238A (zh) | 2014-09-01 | 2021-03-26 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| US10624964B2 (en) | 2015-05-01 | 2020-04-21 | The Trustees Of The University Of Pennsylvania | Methods and compositions for stimulating immune response using potent immunostimulatory RNA motifs |
| CR20180229A (es) | 2015-10-29 | 2018-08-24 | Novartis Ag | Conjugados de anticuerpos que comprenden un agonista del receptor tipo toll |
| KR20180124014A (ko) * | 2015-12-15 | 2018-11-20 | 인스티튜트 내셔널 드 라 싼테 에 드 라 리셰르셰 메디칼르 (인 썸) | Ebv-세포 항원 및 표적화 모이어티를 포함하는 면역원성 컨스트럭트 및 그의 응용 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN106943598A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技(北京)有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| MX2018010485A (es) | 2016-03-04 | 2019-01-10 | Jn Biosciences Llc | Anticuerpos para inmunoreceptor de celulas t con dominios de ig e itim (tigit). |
| CA3049791A1 (en) * | 2017-01-27 | 2018-08-02 | Silverback Therapeutics, Inc. | Tumor targeting conjugates and methods of use thereof |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| FI3641771T3 (fi) | 2017-06-23 | 2026-08-11 | Birdie Biopharmaceuticals Inc | Farmaseuttisia koostumuksia |
| JP2020526482A (ja) * | 2017-06-28 | 2020-08-31 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | デクチン−2刺激及び癌免疫療法のための方法及び組成物 |
| WO2020154424A1 (en) * | 2019-01-22 | 2020-07-30 | The Brigham And Women's Hospital, Inc. | Antigen-presenting neutrophil-derived dendritic cells and methods of use thereof |
| WO2020243616A1 (en) * | 2019-05-31 | 2020-12-03 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | E-cadherin activating antibodies and uses thereof |
| KR20220131895A (ko) * | 2019-11-21 | 2022-09-29 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 항-pd-1/il-15 면역사이토카인을 이용하여 pd-1을 표적으로 하는 신규한 면역요법 |
| US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
| US20230183366A1 (en) | 2020-05-13 | 2023-06-15 | Inserm (Institut National De La Santé Et De La Recherch Médicale) | Recombinant proteins with ox40 activating properties |
| CA3184802A1 (en) | 2020-05-26 | 2021-12-02 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes |
| TW202210514A (zh) | 2020-06-02 | 2022-03-16 | 美商阿克思生物科學有限公司 | 針對tigit的抗體 |
| KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
| CN111850006B (zh) * | 2020-07-27 | 2022-04-22 | 齐鲁工业大学 | 一种适用于低钙离子浓度的纤维小体对接蛋白组合突变体36865及应用 |
| JP2023554587A (ja) | 2020-11-12 | 2023-12-28 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | Sars-cov-2 スパイクタンパク質の受容体結合ドメインにコンジュゲートまたは融合している抗体およびワクチン目的でのそれらの使用 |
| TW202237648A (zh) * | 2020-11-18 | 2022-10-01 | 美商開拓免疫醫療公司 | 抗marco抗體及其用途 |
| US20240131138A1 (en) | 2020-12-23 | 2024-04-25 | Institut National De La Santé Et De La Recherche Médicale (Inserm) | Chlamydia vaccine based on targeting momp vs4 antigen to antigen presenting cells |
| MX2023008986A (es) | 2021-01-29 | 2023-08-15 | Inst Nat Sante Rech Med | Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna. |
| CN118555970A (zh) * | 2021-11-04 | 2024-08-27 | 总医院有限公司 | 抗间皮素抗体试剂 |
| JP2024540505A (ja) | 2021-11-17 | 2024-10-31 | アンスティチュート、ナシオナル、ドゥ、ラ、サンテ、エ、ドゥ、ラ、ルシェルシュ、メディカル | ユニバーサルサルベコウイルスワクチン |
| CN119948059A (zh) | 2022-10-05 | 2025-05-06 | 法国国家健康医学研究院 | 靶向dc的抗尼帕病毒感染疫苗 |
| EP4601682A1 (en) * | 2022-10-13 | 2025-08-20 | The Brigham & Women's Hospital, Inc. | Methods and compositions for improving response to immunotherapy |
| KR102878250B1 (ko) * | 2023-01-11 | 2025-10-31 | 서울대학교산학협력단 | 코리스메이트 뮤테이즈 단백질 또는 이를 암호화하는 폴리뉴클레오티드를 포함하는 암 예방 또는 치료용 조성물 |
| EP4695289A1 (en) * | 2023-04-13 | 2026-02-18 | The Regents of the University of California | Isoform-independent antibodies to lipoprotein(a) |
| WO2026139467A1 (en) | 2024-12-23 | 2026-07-02 | Institut National de la Santé et de la Recherche Médicale | Methods for producing vesicles and applications thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1109356A (zh) * | 1994-09-19 | 1995-10-04 | 中国医学科学院医药生物技术研究所 | 新型免疫佐剂 |
| WO2007103048A2 (en) * | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| WO2008118587A2 (en) * | 2007-02-23 | 2008-10-02 | Baylor Research Institute | Therapeutic applications of activation of human antigen-presenting cells through dectin-1 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200303759A (en) * | 2001-11-27 | 2003-09-16 | Schering Corp | Methods for treating cancer |
| US9259459B2 (en) * | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
| ES2555544T3 (es) * | 2006-03-07 | 2016-01-04 | Vaxinnate Corporation | Composiciones que incluyen hemaglutinina, métodos de preparación y métodos de uso de las mismas |
| US8057798B2 (en) * | 2007-02-02 | 2011-11-15 | Baylor Research Institute | Vaccines based on targeting antigen to DCIR expressed on antigen-presenting cells |
| US8236318B2 (en) * | 2007-11-07 | 2012-08-07 | Celldex Therapeutics Inc. | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
| WO2010009346A2 (en) * | 2008-07-16 | 2010-01-21 | Baylor Research Institute | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
| BRPI1009455A2 (pt) * | 2009-03-10 | 2016-03-01 | Baylor Res Inst | anticorpos anti-c40 e usos dos mesmos |
| CN108373509A (zh) * | 2009-03-10 | 2018-08-07 | 贝勒研究院 | 靶向抗原呈递细胞的抗病毒疫苗 |
| BRPI1009454A2 (pt) * | 2009-03-10 | 2019-09-24 | Baylor Res Institute | vacinas contra o câncer direcionadas a células apresentadoras de antígenos |
| CA2798616A1 (en) * | 2010-05-07 | 2011-11-10 | Baylor Research Institute | Dendritic cell immunoreceptors (dcir)-mediated crosspriming of human cd8+ t cells |
-
2011
- 2011-08-12 KR KR1020137006354A patent/KR20130108295A/ko not_active Withdrawn
- 2011-08-12 US US13/208,993 patent/US20120039916A1/en not_active Abandoned
- 2011-08-12 CA CA2807585A patent/CA2807585A1/en not_active Abandoned
- 2011-08-12 RU RU2013110889/10A patent/RU2013110889A/ru unknown
- 2011-08-12 JP JP2013524253A patent/JP2013535508A/ja active Pending
- 2011-08-12 AU AU2011289234A patent/AU2011289234B2/en not_active Ceased
- 2011-08-12 TW TW100128970A patent/TWI506035B/zh not_active IP Right Cessation
- 2011-08-12 BR BR112013002940A patent/BR112013002940A2/pt not_active IP Right Cessation
- 2011-08-12 MX MX2013001527A patent/MX2013001527A/es not_active Application Discontinuation
- 2011-08-12 WO PCT/US2011/047633 patent/WO2012021834A1/en not_active Ceased
- 2011-08-12 AR ARP110102955A patent/AR082686A1/es not_active Application Discontinuation
- 2011-08-12 CN CN2011800489046A patent/CN103328005A/zh active Pending
- 2011-08-12 EP EP11817128.9A patent/EP2603235A4/en not_active Withdrawn
-
2013
- 2013-02-06 ZA ZA2013/01013A patent/ZA201301013B/en unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1109356A (zh) * | 1994-09-19 | 1995-10-04 | 中国医学科学院医药生物技术研究所 | 新型免疫佐剂 |
| WO2007103048A2 (en) * | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| WO2008118587A2 (en) * | 2007-02-23 | 2008-10-02 | Baylor Research Institute | Therapeutic applications of activation of human antigen-presenting cells through dectin-1 |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107098970B (zh) * | 2007-05-03 | 2021-11-23 | 新加坡科技研究局 | 结合细胞内prl-1多肽或prl-3多肽的抗体 |
| CN107098970A (zh) * | 2007-05-03 | 2017-08-29 | 新加坡科技研究局 | 结合细胞内prl‑1多肽或prl‑3多肽的抗体 |
| CN106170299A (zh) * | 2014-01-22 | 2016-11-30 | 小利兰斯坦福大学托管委员会 | 用于抗体和抗体负载树突状细胞介导治疗的方法和组合物 |
| CN106456736A (zh) * | 2014-06-02 | 2017-02-22 | 贝勒研究院 | 用于治疗过敏和炎性疾病的方法和组合物 |
| CN104689313A (zh) * | 2015-03-04 | 2015-06-10 | 中国科学院海洋研究所 | 大菱鲆cd83分子作为疫苗佐剂的应用 |
| CN108430498A (zh) * | 2015-11-10 | 2018-08-21 | 耶鲁大学 | 用于治疗自身免疫疾病和癌症的组合物及方法 |
| US11110178B2 (en) | 2016-07-07 | 2021-09-07 | The Board Of Trustees Of The Leland Standford Junior University | Antibody adjuvant conjugates |
| US11547761B1 (en) | 2016-07-07 | 2023-01-10 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| CN108727503A (zh) * | 2017-04-18 | 2018-11-02 | 武汉博沃生物科技有限公司 | VZV重组gE-鞭毛素融合蛋白及其制备方法和应用 |
| CN111432833A (zh) * | 2017-11-29 | 2020-07-17 | 自适应噬菌体治疗公司 | 使用二十面体噬菌体的疫苗接种方法 |
| CN111801100A (zh) * | 2018-02-28 | 2020-10-20 | 豪夫迈·罗氏有限公司 | 用于治疗和预防肝癌的7-取代的磺亚氨酰基嘌呤酮化合物和衍生物 |
| CN111801100B (zh) * | 2018-02-28 | 2023-10-24 | 豪夫迈·罗氏有限公司 | 用于治疗和预防肝癌的7-取代的磺亚氨酰基嘌呤酮化合物和衍生物 |
| US11400164B2 (en) | 2019-03-15 | 2022-08-02 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| CN113811547A (zh) * | 2019-03-27 | 2021-12-17 | 国家医疗保健研究所 | 具有cd40激活特性的重组蛋白 |
| CN113811547B (zh) * | 2019-03-27 | 2024-06-25 | 国家医疗保健研究所 | 具有cd40激活特性的重组蛋白 |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112013002940A2 (pt) | 2019-09-24 |
| TWI506035B (zh) | 2015-11-01 |
| US20120039916A1 (en) | 2012-02-16 |
| EP2603235A4 (en) | 2014-04-09 |
| AR082686A1 (es) | 2012-12-26 |
| TW201208696A (en) | 2012-03-01 |
| JP2013535508A (ja) | 2013-09-12 |
| KR20130108295A (ko) | 2013-10-02 |
| EP2603235A1 (en) | 2013-06-19 |
| ZA201301013B (en) | 2015-10-28 |
| AU2011289234B2 (en) | 2014-09-11 |
| WO2012021834A1 (en) | 2012-02-16 |
| AU2011289234A1 (en) | 2013-02-21 |
| RU2013110889A (ru) | 2014-09-20 |
| MX2013001527A (es) | 2013-04-24 |
| CA2807585A1 (en) | 2012-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2011289234B2 (en) | Novel vaccine adjuvants based on targeting adjuvants to antibodies directly to antigen-presenting cells | |
| US20120231023A1 (en) | Novel Vaccine Adjuvants Based on Targeting Adjuvants to Antibodies Directly to Antigen-Presenting Cells | |
| US20120121592A1 (en) | Targeting Antigens to Human Dendritic Cells Via DC-Asialoglycoprotein Receptor to Produce IL-10 Regulatory T-Cells | |
| JP5984388B2 (ja) | 最大限のgag及びnefを樹状細胞に対して標的化することに基づくhivワクチン | |
| TWI483734B (zh) | 針對蘭格漢氏細胞(langerhans cells)之疫苗 | |
| JP2022000047A (ja) | T細胞療法用のt細胞を調製する方法 | |
| US9885017B2 (en) | Compositions and methods to immunize against hepatitis C virus | |
| KR20130036246A (ko) | 사람 cd8+ t 세포의 수지상 세포 면역수용체(dcir)-매개 교차프라이밍 | |
| TW201305193A (zh) | 靶向結核病(tb)疫苗之樹突細胞(dc) | |
| JP2016041725A (ja) | GM−CSF及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞 | |
| ZA200401842B (en) | Process for the maturation of dentritic cells and a vaccine. | |
| JP2023502712A (ja) | 抗pd-1/il-15免疫サイトカインによる新しいpd-1標的免疫療法 | |
| JP7750525B2 (ja) | 新規なtlr9アゴニスト | |
| TW201219053A (en) | Targeting antigens to human dendritic cells via DC-asialoglycoprotein receptor to produce IL-10 regulatory T-cells | |
| WO2025208068A2 (en) | T cell receptor constructs and uses thereof | |
| CN115141241A (zh) | 具有微生物疫苗佐剂、肿瘤疫苗佐剂和肿瘤治疗作用的单链脱氧寡核苷酸 | |
| AU2012261597A1 (en) | Vaccines directed to langerhans cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C05 | Deemed withdrawal (patent law before 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130925 |